(NASDAQ: IMCR) Immunocore Holdings's forecast annual revenue growth rate of 12.24% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.02%.
Immunocore Holdings's revenue in 2026 is $412,812,000.On average, 19 Wall Street analysts forecast IMCR's revenue for 2026 to be $23,194,701,744, with the lowest IMCR revenue forecast at $21,634,145,934, and the highest IMCR revenue forecast at $24,808,666,407. On average, 18 Wall Street analysts forecast IMCR's revenue for 2027 to be $25,379,378,147, with the lowest IMCR revenue forecast at $17,223,592,012, and the highest IMCR revenue forecast at $32,093,633,915.
In 2028, IMCR is forecast to generate $30,241,109,710 in revenue, with the lowest revenue forecast at $15,416,338,168 and the highest revenue forecast at $45,157,439,286.